A Phase I Study of LJM716 in Japanese Patients With Advanced Solid Tumors
This study will evaluate safety and tolerability to estimate the MTDand/or recommended dose.
Neoplasms
DRUG: LM716
Incidence of dose-limiting toxicities (DLTs) in the dose escalation part, First cycle (28 days)
Frequency and severity of adverse events, number of and reasons for, from informed consent till 30 days after end of treatment|LJM716 serum concentration-time- profile and estimated PK, up to 10 cycle (1 cycle = 28 days)|Tumor response according to RECIST 1.1, every 2 months until end of treatment up to 2 years|Incidence of antibodies against LJM716, up to 10 cycle ( 1cycle = 28 days)
This is a phase I, open-label, dose-escalation study to establish the MTD and/or RDE of LJM716 as single agent in Japanese patients that have advanced solid tumors. The study consists of a dose escalation part and a dose expansion part.